The massive registered share count (173% of outstanding) creates severe overhang risk, though much is tied up by 4.99%-9.99% beneficial ownership blockers on the warrants. Watch for 424B prospectus supplements signaling actual sales by large holders (Commodore Capital, RA Capital, TCG Crossover)—any reduction in ownership caps via 61-day notice would accelerate selling. The $85M PIPE proceeds should extend runway but with Q1 2026 cash of only $35M (after Q2 2026 $34.5M revenue, largely non-cash), capital needs remain acute.
Price Chart
Executive Summary
Agenus filed a resale registration statement on Form S-3 to register up to 77,976,718 shares of common stock held by selling securityholders from its July 2026 $85M private placement. The filing is a contractual obligation under the Registration Rights Agreement and does not represent a new primary offering—Agenus receives no proceeds from the resale but could receive up to $255M if warrants are exercised for cash. With a $335M market cap, the registered shares represent over 170% of current outstanding shares, creating massive near-term overhang risk even though most warrants are subject to beneficial ownership limitations.
Key Facts
- Registers 77,976,718 shares for resale by selling securityholders, including 1,626,015 issued shares, 21,409,212 pre-funded warrant shares, and 54,941,491 purchase warrant shares
- Registered under Registration Rights Agreement from July 13, 2026 $85M private placement (closed July 15, 2026)
- Agenus receives no proceeds from resale; would receive cash only if warrants exercised—Series A ($4.02 strike) and Series B ($5.03 strike) warrants could yield up to $255M if fully exercised
- Current shares outstanding: 45,009,670 as of July 31, 2026—registered shares equal ~173% of outstanding
- Stock closed at $7.49 on August 6, 2026; Series A and B warrants are in-the-money by $3.47 and $2.46 respectively
- KPMG audit report included a going-concern explanatory paragraph for FY2025 financials
Financial Impact
Max potential warrant exercise proceeds of $255M; registration covers $607.8M in market value of shares at $7.795 reference price
Risk Factors
- Massive potential dilution—registered shares equal ~173% of current outstanding, even with most warrants subject to beneficial ownership caps
- Selling pressure from institutional holders (Commodore Capital, RA Capital, Invus, Ligand, TCG Crossover) who obtained shares at a combined $3.69/unit—now 103% above cost at $7.49
- Going concern risk highlighted by KPMG; pre-revenue clinical-stage company with cash burn and uncertain Phase 3 trial outcomes
- BATTMAN trial terminated due to funding prioritization, narrowing pipeline to botensilimab/balstilimab ROBBIN trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-340213 |
| Document: d120245dexfilingfees.htm | 0001193125-26-340213 |
| Document: d120245dex51.htm | 0001193125-26-340213 |
| Document: d120245dex232.htm | 0001193125-26-340213 |
| Document: 0001193125-26-340213-index-headers.html | 0001193125-26-340213 |
| Document: 0001193125-26-340213-index.html | 0001193125-26-340213 |
| Document: 0001193125-26-340213.txt | 0001193125-26-340213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $7.00 $6.94 | ▼ −0.86% | ▲ +0.89% | $8.15 (+16.50%) |
Aug 12, 2026 7w ago | Institutional Cluster | $6.90 $6.89 | ▼ −0.14% | ▲ +1.75% | $8.15 (+18.19%) |
Aug 7, 2026 7w ago | S-3 | $7.00 $7.76 | ▼ −10.87% | ▼ −11.78% | $8.15 (−16.50%) |
Aug 6, 2026 8w ago | 8-K | $7.49 $8.24 | ▲ +10.01% | ▲ +9.41% | $8.15 (+8.88%) |
Jul 18, 2026 10w ago | S-3 | $4.97 $7.15 | ▼ −43.86% | ▼ −39.74% | $8.15 (−64.08%) |
Jul 13, 2026 11w ago | 8-K | $6.12 $7.00 | ▼ −14.38% | ▼ −11.19% | $8.15 (−33.25%) |
May 13, 2026 20w ago | DEFA14A | $3.47 $3.39 | ▼ −2.31% | ▼ −1.69% | $8.15 (+135.01%) |
May 11, 2026 20w ago | 8-K | $3.26 $3.11 | ▼ −4.60% | ▼ −4.30% | $8.15 (+150.15%) |
Dec 4, 2025 43w ago | Court Ruling | $4.06 $3.22 | ▲ +20.69% | ▲ +21.18% | $8.15 (−100.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access